In CRC, approximately 10–20% of tumors exhibit mutations in the p110α catalytic subunit (predominantly H1047R and E545K substitutions in the PIK3CA gene), causing constitutive PI3K/Akt activation2 and worsening clinical outcome.3 Here, PIK3CA is linked to colorectal carcinoma.